Annual General Meeting

ASX:RCE FSE:R9Q

14 November 2022

Disclaimer

DISCLAIMER

This presentation has been prepared by Recce Pharmaceuticals Ltd (the "Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

FUTURE MATTERS

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US DISCLOSURE

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

Board and Management Structure

Goals Stated at AGM 2021

AGM Presentation, Slide 8, 22 Nov 2021

Clinical Objectives ✓

Phase I (R327) Intravascular Clinical Trial – Patient dosing on track for December ✓
Phase I/II (R327) spray-on antibiotic burn wound studies – Broad Spectrum antibiotic resistant infections among patients dosed ✓

Pre-Clinical Objectives ✓

R327 Australia COVID studies – Advanced to Stage 2 of the program ✓
R327 & R529 COVID (US) – 'gold standard' animal study model underway ✓
Murdoch Children's Research Institute - H. pylori, Sinusitis in-vivo studies, dose optimisation ✓
Mechanism of Action (MoA) studies – Expanded mechanistic insights, journal submission/s – world first ✓

Corporate Objectives ✓

Continue big-pharma discussions position of power with unique MoA & strong cash position ✓
Expand international awareness particular focus on USA and EU ✓
Intellectual Property will continue to strengthen – Strong patent standing & Regulatory Incentive Focused ✓
New Clinical trials to begin Expect existing activities to bring online new clinical trials e.g. diabetic foot ulcers ✓

Recce has delivered!

12 Months of Announcements

Since our last AGM:

Update on Phase I/II Clinical Trial for Burn Wound Infection (07/12/21)
First Patients to be Dosed in Phase I I.V. Clinical Trial of R327 (15/12/21)
Positive Safety Data from Cohort 1 Phase I I.V. Clinical Trial (07/01/22)
Positive Safety Data from Second Cohort of Phase I I.V. Clinical Trial (18/01/22)
Positive Initial Safety Data from Third Cohort of Phase I I.V. Clinical Trial (08/02/22)
Final Subjects Dosed in Cohort 3 Phase I I.V. Clinical Trial (21/02/22)
Safety Committee Clears Phase I I.V. R327 Dose Increase (07/03/22)
$3.08m R&D Rebate Received (28/03/22)
Positive safety data from 4th Cohort Phase I I.V. Clinical Trial (30/03/22)
Anti-Viral Patent Granted in Hong Kong (11/04/22)
Phase I Clinical Trial R327 Advances to High Dose Cohort 2,000mg (12/04/22)

Phase I I.V. Positive Safety Data 4000mg Complete (21/06/22)
Appointment of Dr Philip Sutton as V.P. of Translational Sciences (11/07/22)
Phase I Clinical Trial of R327 I.V. 6000mg Complete (22/08/22)
Appointment of Alistair McKeough to Board of Directors (01/09/22)
Appointment of Dr John Prendergast as Executive Chairman (05/09/22)
Michele Dilizia, CSO, delivers Opening R&D Address at World AMR Congress (07/09/22)
Expansion and Acceleration of Clinical Programs (27/09/22)
R327 COVID Study Update (18/10/22)
Anti-Infective Portfolio Update and Webinar (19/10/22)

*Awarded by the US FDA in 2017 for R327 bacteraemia (broad-spectrum bacterial sepsis). Time starts only from potential market approval.

A Versatile Technology Platform

Biotech company developing Anti-infectives targeting both bacterial and viral indications
Strong IP and own manufacturing capability
Qualified Infectious Disease Product designation
- 10 years market exclusivity plus fast track approval*
Versatile delivery platform oral, intravenous and topical formulations
Designed to safely provide treatment without developing resistance over time
Multiple infectious disease opportunities with RECCE® 327

Strong Pipeline

Over Various Indications and Upcoming Inflection Points

Indications	Discovery	Pre-Clinical	Phase I	Phase II	Phase III	Market
Serious/life threatening bacterialinfections including sepsis
Urinary tract infectionsincluding urosepsis
Multidose, early stage sepsisefficacy study
Wound infectionsincluding infected burns
Diabetic Foot Ulcers
Helicobacter pyloripre-clinical program
Bacterial Sinusitispre-clinical program
Mycobacterium abscessuspre-clinical program
COVID & Influenza
COVID

*Anti-bacterial program **Anti-viral program

Phase I Intravenous Human Clinical Trial

Randomized, double-blind, placebo-controlled, safety, tolerability and pharmacokinetics study.
Single dose of a 1-hour via IV infusion at a uniform rate in hospital setting.
Primary endpoint: vital signs, 12-lead ECG parameters, clinical chemistry, hematology, and

*Dose increase fold based off 50mg

Reason for Optimism in Treating UTI/Sepsis

R327 primary route of elimination appears to be through the kidney to the ureters and bladder.
High concentrations of R327 noted in the urine of Phase I healthy subjects.
Insight consistent with pre-clinical in-vivo kidney and UTI bacterial infection studies.
Opportunities for therapeutic in array of UTIs (uncomplicated UTI - single dose, complicated UTI, recurrent UTI, treatment resistant etc).
Suggests broader anti-infective treatment model in pre-sepsis.

Pre-Clinical Study Outlook

Murdoch Children's Research Institute
- Bacterial Sinusitis Sufficient and compelling data -potential to start a Phase I/II clinical trial
- M. abscessus Proof of concept achieved Compelling data for a potential human study
- H. pylori - Further formulation work and dosing optimisation required to improve delivery to site of infection
Mechanism of Action studies
- Results confirm that R327 is broad spectrum, bactericidal, effective against growing and non-growing cells
R327 COVID Study (Netherlands)
- R327 was shown to significantly reduce SARS-CoV-2 levels in the throat in a dose-dependent manner

Asset andRoute of Administration	Indications	Discovery	Pre-Clinical	Phase I	Phase II
RCE Compounds*	Bacterial Sinusitispre-clinical program
	Helicobacter pyloripre-clinical program
	Mycobacterium abscessuspre-clinical program

Dr Philip Sutton's Pre-Clinical Update

Topical RECCE® 327 – Phase I/II

Patient examples from ongoing Burn Wound trial

Patients suffered major burn injury.
Multiple bacterial species in and surrounding wound.
Growth swabs with organisms including pathogens from the ESKAPE group of bacteria.
Post R327 treatment: healthy skin growth return, reduced swelling and infection, indications of tissue penetration to underlying infection.

Study data now under-review for next-step considerations.

• Building upon the success of these results, the Company has built out its topical treatment programs to include a new Phase II clinical study for Diabetic Foot Ulcer infections.

Pre-treatment, significant bacterial infection Post R327 treatment

Phase II Diabetic Foot Ulcer (DFU) Clinical Trial

Clinical Trial Overview

The Phase II DFU Clinical Trial is expected to be held at a leading Australian teaching hospital.
The clinical trial will assess R327 as a spray-on (topical) broad-spectrum antibiotic therapy for mild skin and soft tissue diabetic foot ulcers (DFU).

Market Opportunity

The total medical cost for treating diabetic foot diseases in the United States is US $9-13 billion every year.¹
DFU is a chronic and devastating condition affecting an estimated 43,147,000 (13%) of the United States population.¹

Recce Executives and NSW Health Clinical Trial Team

Upcoming Clinical Milestones

In-vivo pre-clinical
- ‒ Pre-Sepsis UTI Models in Rats ✓
Phase I clinical trials
- ‒ R327 I.V. Single Dose, Safety/Tolerability/PK study in healthy subjects ✓
Phase II UTI clinical trial (Pre-Sepsis)
- ‒ Single (as now completed Phase I) efficacy study Q1 2023
- ‒ Multiple-dose treatment of UTIs complicated/resistant/chronic/etc. H1 2023
Phase Ib/IIa Sepsis clinical trial
- ‒ R327 I.V. Multiple Dose, Safety/Tolerability/PK study in healthy subjects (First patient dosing Q4 2022)
- ‒ Multiple-Dose efficacy study in urosepsis* (sepsis derived from UTI infections) efficacy signal
Phase II Diabetic Foot Ulcer (DFU) clinical trial
- ‒ R327 as a spray-on (topical) broad-spectrum antibiotic for mild skin and soft tissue DFU (First patient dosing expected Q4 2022)